{
  "id": 11468373,
  "title": "Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus",
  "url": "https://urgent.news/2026/10/02/biogens-litifilimab-demonstrates-rapid-and-durable-efficacy-in-new-52",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-02T15:25:52.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/biogens-litifilimab-demonstrates-rapid-and-durable-efficacy-in-new-52-week-phase-2-data-from-ongoing-phase-2-3-amethyst-study-reinforcing-its-potential-as-a-first-in-class-therapy-for-cutaneous-lup"
  },
  "original_language": "en",
  "account": null,
  "summary": "Biogen Inc. has unveiled new 52-week Phase 2 data from the AMETHYST study for its investigational drug litifilimab, which demonstrates rapid and durable efficacy in treating cutaneous lupus erythematosus (CLE). The study, presented at the EADV 2026 Congress, builds upon previous data and provides the longest dataset for litifilimab in CLE patients. Participants receiving litifilimab in the double-blind, placebo-controlled phase showed continued improvement in skin disease activity up to Week 52. Notably, those who began treatment with litifilimab after switching from placebo at Week 24 experienced a rapid onset of treatment effects within just four weeks.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}